LymphedemaV1, PascalFrancis, Curation, bibRecord, 000260

Quantitative radionuclide lymphoscintigraphy predicts outcome of manual lymphatic therapy in breast cancer-related lymphedema of the upper extremity

Identifieur interne : 000260 ( PascalFrancis/Curation ); précédent : 000259; suivant : 000261

Quantitative radionuclide lymphoscintigraphy predicts outcome of manual lymphatic therapy in breast cancer-related lymphedema of the upper extremity

Auteurs : A. Szuba [États-Unis] ; W. Strauss [Canada] ; S. P. Sirsikar [États-Unis] ; S. G. Rockson [États-Unis]

Source :

Nuclear medicine communications [ 0143-3636 ] ; 2002.

RBID : Pascal:03-0180969

Descripteurs français

Pascal (Inist)
- Scintigraphie, Lymphatique, Traitement manuel, Lymphoedème, Extrémité supérieure, Tumeur maligne, Glande mammaire, Mastectomie, Drainage, Postopératoire, Analyse quantitative, Surveillance, Efficacité traitement, Homme, Femelle, Prospective, Etude cas.
Wicri :
- topic : Drainage, Analyse quantitative, Homme, Prospective.

English descriptors

KwdEn :
- Case study, Drainage, Female, Human, Lymphatic, Lymphedema, Malignant tumor, Mammary gland, Manual processing, Mastectomy, Postoperative, Prospective, Quantitative analysis, Scintigraphy, Surveillance, Treatment efficiency, Upper extremity.

Abstract

Secondary lymphedema is a localized, acquired lymphatic microcirculatory disturbance that affects large numbers of patients after breast cancer therapy. There is a paucity of objective methods to quantitate lymphatic function and to anticipate the response to therapeutic interventions. We applied radionuclide lymphoscintigraphy to evaluate lymphatic transport and axillary lymph node visualization in women following breast cancer therapy to determine the utility of these data in these patients. Lymphoscintigraphy was performed after subcutaneous injection of 0.25 mCi of ^99mTc-filtered sulfur colloid. Subcutaneous accumulation of radiotracer ('dermal backflow') and the visualization of axillary lymph nodes were graded using our own scoring system. The ratio of radioactivity within the affected to normal axillae (ARR) was also quantified. Nineteen patients with lymphedema after breast cancer therapy were evaluated. The disease severity was documented by serial measurements of the limb volume using the truncated cone formula. Responses to therapy were quantified after completion of the therapy. There was a correlation between the ARR and the percentage reduction in edema volume. The lymphoscintigraphic score correlated with the initial arm volume excess and with the duration of lymphedema. It can be concluded that quantitative and semi-quantitative assessment by radionuclide lymphoscintigraphy represents a potentially useful tool for the clinical assessment of upper extremity lymphedema.

A01	`01`	`1`		`@0 0143-3636`
A03		`1`		`@0 Nucl. med. commun.`
A05				`@2 23`
A06				`@2 12`
A08	`01`	`1`	`ENG`	`@1 Quantitative radionuclide lymphoscintigraphy predicts outcome of manual lymphatic therapy in breast cancer-related lymphedema of the upper extremity`
A11	`01`	`1`		`@1 SZUBA (A.)`
A11	`02`	`1`		`@1 STRAUSS (W.)`
A11	`03`	`1`		`@1 SIRSIKAR (S. P.)`
A11	`04`	`1`		`@1 ROCKSON (S. G.)`
A14	`01`			`@1 Stanford Center for Lymphatic and Venous Disorders, Division of Cardiovascular Medicine, Stanford University School of Medicine @2 Stanford, CA @3 USA @Z 1 aut. @Z 3 aut. @Z 4 aut.`
A14	`02`			`@1 Division of Nuclear Medicine, Stanford University School of Medicine @2 Stanford, CA @3 CAN @Z 2 aut.`
A20				`@1 1171-1175`
A21				`@1 2002`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 21691 @5 354000103719470030`
A44				`@0 0000 @1 © 2003 INIST-CNRS. All rights reserved.`
A45				`@0 12 ref.`
A47	`01`	`1`		`@0 03-0180969`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Nuclear medicine communications`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Secondary lymphedema is a localized, acquired lymphatic microcirculatory disturbance that affects large numbers of patients after breast cancer therapy. There is a paucity of objective methods to quantitate lymphatic function and to anticipate the response to therapeutic interventions. We applied radionuclide lymphoscintigraphy to evaluate lymphatic transport and axillary lymph node visualization in women following breast cancer therapy to determine the utility of these data in these patients. Lymphoscintigraphy was performed after subcutaneous injection of 0.25 mCi of ^99mTc-filtered sulfur colloid. Subcutaneous accumulation of radiotracer ('dermal backflow') and the visualization of axillary lymph nodes were graded using our own scoring system. The ratio of radioactivity within the affected to normal axillae (ARR) was also quantified. Nineteen patients with lymphedema after breast cancer therapy were evaluated. The disease severity was documented by serial measurements of the limb volume using the truncated cone formula. Responses to therapy were quantified after completion of the therapy. There was a correlation between the ARR and the percentage reduction in edema volume. The lymphoscintigraphic score correlated with the initial arm volume excess and with the duration of lymphedema. It can be concluded that quantitative and semi-quantitative assessment by radionuclide lymphoscintigraphy represents a potentially useful tool for the clinical assessment of upper extremity lymphedema.
C02	`01`	`X`		`@0 002B12B04`
C03	`01`	`X`	`FRE`	`@0 Scintigraphie @5 01`
C03	`01`	`X`	`ENG`	`@0 Scintigraphy @5 01`
C03	`01`	`X`	`SPA`	`@0 Centelleografía @5 01`
C03	`02`	`X`	`FRE`	`@0 Lymphatique @5 02`
C03	`02`	`X`	`ENG`	`@0 Lymphatic @5 02`
C03	`02`	`X`	`SPA`	`@0 Linfático @5 02`
C03	`03`	`X`	`FRE`	`@0 Traitement manuel @5 04`
C03	`03`	`X`	`ENG`	`@0 Manual processing @5 04`
C03	`03`	`X`	`SPA`	`@0 Tratamiento manual @5 04`
C03	`04`	`X`	`FRE`	`@0 Lymphoedème @5 07`
C03	`04`	`X`	`ENG`	`@0 Lymphedema @5 07`
C03	`04`	`X`	`SPA`	`@0 Linfedema @5 07`
C03	`05`	`X`	`FRE`	`@0 Extrémité supérieure @5 08`
C03	`05`	`X`	`ENG`	`@0 Upper extremity @5 08`
C03	`05`	`X`	`SPA`	`@0 Extremidad superior @5 08`
C03	`06`	`X`	`FRE`	`@0 Tumeur maligne @5 10`
C03	`06`	`X`	`ENG`	`@0 Malignant tumor @5 10`
C03	`06`	`X`	`SPA`	`@0 Tumor maligno @5 10`
C03	`07`	`X`	`FRE`	`@0 Glande mammaire @5 11`
C03	`07`	`X`	`ENG`	`@0 Mammary gland @5 11`
C03	`07`	`X`	`SPA`	`@0 Glándula mamaria @5 11`
C03	`08`	`X`	`FRE`	`@0 Mastectomie @5 13`
C03	`08`	`X`	`ENG`	`@0 Mastectomy @5 13`
C03	`08`	`X`	`SPA`	`@0 Mastectomía @5 13`
C03	`09`	`X`	`FRE`	`@0 Drainage @5 14`
C03	`09`	`X`	`ENG`	`@0 Drainage @5 14`
C03	`09`	`X`	`SPA`	`@0 Drenaje @5 14`
C03	`10`	`X`	`FRE`	`@0 Postopératoire @5 16`
C03	`10`	`X`	`ENG`	`@0 Postoperative @5 16`
C03	`10`	`X`	`SPA`	`@0 Postoperatorio @5 16`
C03	`11`	`X`	`FRE`	`@0 Analyse quantitative @5 17`
C03	`11`	`X`	`ENG`	`@0 Quantitative analysis @5 17`
C03	`11`	`X`	`SPA`	`@0 Análisis cuantitativo @5 17`
C03	`12`	`X`	`FRE`	`@0 Surveillance @5 18`
C03	`12`	`X`	`ENG`	`@0 Surveillance @5 18`
C03	`12`	`X`	`SPA`	`@0 Vigilancia @5 18`
C03	`13`	`X`	`FRE`	`@0 Efficacité traitement @5 19`
C03	`13`	`X`	`ENG`	`@0 Treatment efficiency @5 19`
C03	`13`	`X`	`SPA`	`@0 Eficacia tratamiento @5 19`
C03	`14`	`X`	`FRE`	`@0 Homme @5 20`
C03	`14`	`X`	`ENG`	`@0 Human @5 20`
C03	`14`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`15`	`X`	`FRE`	`@0 Femelle @5 21`
C03	`15`	`X`	`ENG`	`@0 Female @5 21`
C03	`15`	`X`	`SPA`	`@0 Hembra @5 21`
C03	`16`	`X`	`FRE`	`@0 Prospective @5 23`
C03	`16`	`X`	`ENG`	`@0 Prospective @5 23`
C03	`16`	`X`	`SPA`	`@0 Prospectiva @5 23`
C03	`17`	`X`	`FRE`	`@0 Etude cas @5 24`
C03	`17`	`X`	`ENG`	`@0 Case study @5 24`
C03	`17`	`X`	`SPA`	`@0 Estudio caso @5 24`
C07	`01`	`X`	`FRE`	`@0 Exploration radioisotopique @5 37`
C07	`01`	`X`	`ENG`	`@0 Radionuclide study @5 37`
C07	`01`	`X`	`SPA`	`@0 Exploración radioisotópica @5 37`
C07	`02`	`X`	`FRE`	`@0 Imagerie médicale @5 38`
C07	`02`	`X`	`ENG`	`@0 Medical imagery @5 38`
C07	`02`	`X`	`SPA`	`@0 Imaginería médica @5 38`
C07	`03`	`X`	`FRE`	`@0 Appareil circulatoire pathologie @5 53`
C07	`03`	`X`	`ENG`	`@0 Cardiovascular disease @5 53`
C07	`03`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 53`
C07	`04`	`X`	`FRE`	`@0 Lymphatique pathologie @5 54`
C07	`04`	`X`	`ENG`	`@0 Lymphatic vessel disease @5 54`
C07	`04`	`X`	`SPA`	`@0 Linfático patología @5 54`
C07	`05`	`X`	`FRE`	`@0 Glande mammaire pathologie @2 NM @5 61`
C07	`05`	`X`	`ENG`	`@0 Mammary gland diseases @2 NM @5 61`
C07	`05`	`X`	`SPA`	`@0 Glándula mamaria patología @2 NM @5 61`
C07	`06`	`X`	`FRE`	`@0 Chirurgie @5 69`
C07	`06`	`X`	`ENG`	`@0 Surgery @5 69`
C07	`06`	`X`	`SPA`	`@0 Cirugía @5 69`
N21				`@1 104`
N82				`@1 PSI`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000700

Links to Exploration step

Pascal:03-0180969

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Quantitative radionuclide lymphoscintigraphy predicts outcome of manual lymphatic therapy in breast cancer-related lymphedema of the upper extremity</title>
<author><name sortKey="Szuba, A" sort="Szuba, A" uniqKey="Szuba A" first="A." last="Szuba">A. Szuba</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Stanford Center for Lymphatic and Venous Disorders, Division of Cardiovascular Medicine, Stanford University School of Medicine</s1>
<s2>Stanford, CA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Strauss, W" sort="Strauss, W" uniqKey="Strauss W" first="W." last="Strauss">W. Strauss</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Nuclear Medicine, Stanford University School of Medicine</s1>
<s2> Stanford, CA</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Sirsikar, S P" sort="Sirsikar, S P" uniqKey="Sirsikar S" first="S. P." last="Sirsikar">S. P. Sirsikar</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Stanford Center for Lymphatic and Venous Disorders, Division of Cardiovascular Medicine, Stanford University School of Medicine</s1>
<s2>Stanford, CA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Rockson, S G" sort="Rockson, S G" uniqKey="Rockson S" first="S. G." last="Rockson">S. G. Rockson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Stanford Center for Lymphatic and Venous Disorders, Division of Cardiovascular Medicine, Stanford University School of Medicine</s1>
<s2>Stanford, CA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0180969</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 03-0180969 INIST</idno>
<idno type="RBID">Pascal:03-0180969</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000700</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000260</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Quantitative radionuclide lymphoscintigraphy predicts outcome of manual lymphatic therapy in breast cancer-related lymphedema of the upper extremity</title>
<author><name sortKey="Szuba, A" sort="Szuba, A" uniqKey="Szuba A" first="A." last="Szuba">A. Szuba</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Stanford Center for Lymphatic and Venous Disorders, Division of Cardiovascular Medicine, Stanford University School of Medicine</s1>
<s2>Stanford, CA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Strauss, W" sort="Strauss, W" uniqKey="Strauss W" first="W." last="Strauss">W. Strauss</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Nuclear Medicine, Stanford University School of Medicine</s1>
<s2> Stanford, CA</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Sirsikar, S P" sort="Sirsikar, S P" uniqKey="Sirsikar S" first="S. P." last="Sirsikar">S. P. Sirsikar</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Stanford Center for Lymphatic and Venous Disorders, Division of Cardiovascular Medicine, Stanford University School of Medicine</s1>
<s2>Stanford, CA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Rockson, S G" sort="Rockson, S G" uniqKey="Rockson S" first="S. G." last="Rockson">S. G. Rockson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Stanford Center for Lymphatic and Venous Disorders, Division of Cardiovascular Medicine, Stanford University School of Medicine</s1>
<s2>Stanford, CA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Nuclear medicine communications</title>
<title level="j" type="abbreviated">Nucl. med. commun.</title>
<idno type="ISSN">0143-3636</idno>
<imprint><date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Nuclear medicine communications</title>
<title level="j" type="abbreviated">Nucl. med. commun.</title>
<idno type="ISSN">0143-3636</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Case study</term>
<term>Drainage</term>
<term>Female</term>
<term>Human</term>
<term>Lymphatic</term>
<term>Lymphedema</term>
<term>Malignant tumor</term>
<term>Mammary gland</term>
<term>Manual processing</term>
<term>Mastectomy</term>
<term>Postoperative</term>
<term>Prospective</term>
<term>Quantitative analysis</term>
<term>Scintigraphy</term>
<term>Surveillance</term>
<term>Treatment efficiency</term>
<term>Upper extremity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Scintigraphie</term>
<term>Lymphatique</term>
<term>Traitement manuel</term>
<term>Lymphoedème</term>
<term>Extrémité supérieure</term>
<term>Tumeur maligne</term>
<term>Glande mammaire</term>
<term>Mastectomie</term>
<term>Drainage</term>
<term>Postopératoire</term>
<term>Analyse quantitative</term>
<term>Surveillance</term>
<term>Efficacité traitement</term>
<term>Homme</term>
<term>Femelle</term>
<term>Prospective</term>
<term>Etude cas</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Drainage</term>
<term>Analyse quantitative</term>
<term>Homme</term>
<term>Prospective</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Secondary lymphedema is a localized, acquired lymphatic microcirculatory disturbance that affects large numbers of patients after breast cancer therapy. There is a paucity of objective methods to quantitate lymphatic function and to anticipate the response to therapeutic interventions. We applied radionuclide lymphoscintigraphy to evaluate lymphatic transport and axillary lymph node visualization in women following breast cancer therapy to determine the utility of these data in these patients. Lymphoscintigraphy was performed after subcutaneous injection of 0.25 mCi of <sup>99m</sup>
Tc-filtered sulfur colloid. Subcutaneous accumulation of radiotracer ('dermal backflow') and the visualization of axillary lymph nodes were graded using our own scoring system. The ratio of radioactivity within the affected to normal axillae (ARR) was also quantified. Nineteen patients with lymphedema after breast cancer therapy were evaluated. The disease severity was documented by serial measurements of the limb volume using the truncated cone formula. Responses to therapy were quantified after completion of the therapy. There was a correlation between the ARR and the percentage reduction in edema volume. The lymphoscintigraphic score correlated with the initial arm volume excess and with the duration of lymphedema. It can be concluded that quantitative and semi-quantitative assessment by radionuclide lymphoscintigraphy represents a potentially useful tool for the clinical assessment of upper extremity lymphedema.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0143-3636</s0>
</fA01>
<fA03 i2="1"><s0>Nucl. med. commun.</s0>
</fA03>
<fA05><s2>23</s2>
</fA05>
<fA06><s2>12</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Quantitative radionuclide lymphoscintigraphy predicts outcome of manual lymphatic therapy in breast cancer-related lymphedema of the upper extremity</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SZUBA (A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>STRAUSS (W.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>SIRSIKAR (S. P.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>ROCKSON (S. G.)</s1>
</fA11>
<fA14 i1="01"><s1>Stanford Center for Lymphatic and Venous Disorders, Division of Cardiovascular Medicine, Stanford University School of Medicine</s1>
<s2>Stanford, CA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Division of Nuclear Medicine, Stanford University School of Medicine</s1>
<s2> Stanford, CA</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA20><s1>1171-1175</s1>
</fA20>
<fA21><s1>2002</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>21691</s2>
<s5>354000103719470030</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2003 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>12 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>03-0180969</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Nuclear medicine communications</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Secondary lymphedema is a localized, acquired lymphatic microcirculatory disturbance that affects large numbers of patients after breast cancer therapy. There is a paucity of objective methods to quantitate lymphatic function and to anticipate the response to therapeutic interventions. We applied radionuclide lymphoscintigraphy to evaluate lymphatic transport and axillary lymph node visualization in women following breast cancer therapy to determine the utility of these data in these patients. Lymphoscintigraphy was performed after subcutaneous injection of 0.25 mCi of <sup>99m</sup>
Tc-filtered sulfur colloid. Subcutaneous accumulation of radiotracer ('dermal backflow') and the visualization of axillary lymph nodes were graded using our own scoring system. The ratio of radioactivity within the affected to normal axillae (ARR) was also quantified. Nineteen patients with lymphedema after breast cancer therapy were evaluated. The disease severity was documented by serial measurements of the limb volume using the truncated cone formula. Responses to therapy were quantified after completion of the therapy. There was a correlation between the ARR and the percentage reduction in edema volume. The lymphoscintigraphic score correlated with the initial arm volume excess and with the duration of lymphedema. It can be concluded that quantitative and semi-quantitative assessment by radionuclide lymphoscintigraphy represents a potentially useful tool for the clinical assessment of upper extremity lymphedema.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B12B04</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Scintigraphie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Scintigraphy</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Centelleografía</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Lymphatique</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Lymphatic</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Linfático</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Traitement manuel</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Manual processing</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tratamiento manual</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Lymphoedème</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Lymphedema</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Linfedema</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Extrémité supérieure</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Upper extremity</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Extremidad superior</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Glande mammaire</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Mammary gland</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Glándula mamaria</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Mastectomie</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Mastectomy</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Mastectomía</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Drainage</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Drainage</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Drenaje</s0>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Postopératoire</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Postoperative</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Postoperatorio</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Analyse quantitative</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Quantitative analysis</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Análisis cuantitativo</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Surveillance</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Surveillance</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Vigilancia</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Efficacité traitement</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Treatment efficiency</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Eficacia tratamiento</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Femelle</s0>
<s5>21</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Female</s0>
<s5>21</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Hembra</s0>
<s5>21</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Prospective</s0>
<s5>23</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Prospective</s0>
<s5>23</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Prospectiva</s0>
<s5>23</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Etude cas</s0>
<s5>24</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Case study</s0>
<s5>24</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Estudio caso</s0>
<s5>24</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Exploration radioisotopique</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Radionuclide study</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Exploración radioisotópica</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Imagerie médicale</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Medical imagery</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Imaginería médica</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Appareil circulatoire pathologie</s0>
<s5>53</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>53</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>53</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Lymphatique pathologie</s0>
<s5>54</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Lymphatic vessel disease</s0>
<s5>54</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Linfático patología</s0>
<s5>54</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Glande mammaire pathologie</s0>
<s2>NM</s2>
<s5>61</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Mammary gland diseases</s0>
<s2>NM</s2>
<s5>61</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Glándula mamaria patología</s0>
<s2>NM</s2>
<s5>61</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Chirurgie</s0>
<s5>69</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Surgery</s0>
<s5>69</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Cirugía</s0>
<s5>69</s5>
</fC07>
<fN21><s1>104</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000260 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000260 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:03-0180969
   |texte=   Quantitative radionuclide lymphoscintigraphy predicts outcome of manual lymphatic therapy in breast cancer-related lymphedema of the upper extremity
}}

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Quantitative radionuclide lymphoscintigraphy predicts outcome of manual lymphatic therapy in breast cancer-related lymphedema of the upper extremity

Quantitative radionuclide lymphoscintigraphy predicts outcome of manual lymphatic therapy in breast cancer-related lymphedema of the upper extremity

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri